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dustrial and InformationIn 1956, Blankerhorn and Gall [1] proposed the term
myocarditis for inﬂammatory heart muscle disease, and
myocardiosis for other heart muscle diseases. A year there-
after, Brigden [2] deﬁned cardiomyopathies as uncommon,
non-coronary heart muscle diseases. Subsequently, Good-
win and Oakley [3] deﬁned cardiomyopathies as myocardial
diseases of unknown origin, and proposed categorization of
the disorders as dilated (DCM), hypertrophic (HCM), and
restrictive (or obliterative) (RCM) cardiomyopathies. In
1980, the World Health Organization (WHO) and Interna-
tional Society and Federation of Cardiology (ISFC) estab-
lished the deﬁnition of cardiomyopathies as myocardial
diseases of unknown etiology, reﬂecting the general lack of
information about themechanism(s) of disease [4]. Although
WHO-ISFC retained the 3 morphological types of cardio-
myopathies proposed by Goodwin and Oakley, it also
introduced the term speciﬁc heart muscle disease, where the
cause of myocardial dysfunction was known. The WHO-
ISFC classiﬁcation subsequently expanded the deﬁnition of
cardiomyopathies by adding the functional component and
deﬁned cardiomyopathy as the diseases of myocardium
associated with myocardial dysfunction. Two additional
classes, arrhythmogenic right ventricular cardiomyopathy
(ARVC) and unclassiﬁed cardiomyopathy, were introduced
during the revision, and the category of the speciﬁc heart
muscle disease was excluded [5]. The ISFC changed its name
to the World Heart Federation (WHF) in 1998 [6], and did
not indulge in further revision of the recommendations for
either diagnosis or management of cardiomyopathies.
A substantial increase in the knowledge of the genetic
basis of cardiomyopathy has occurred, and noninvasive
phenotypic characterization has become signiﬁcantly more
sophisticated. Therefore, the American Heart Association
(AHA) [7] and the European Society of Cardiology (ESC) [8]
in the last decade have proposed revisions to the classiﬁ-
cation of cardiomyopathic disorders. Whereas both
systems have substantial similarities and have made
important recommendations, the former has described
cardiomyopathies starting from the genetic basis of the eti-
ology followed by the phenotypic description of myocardial
involvement. Conversely, the ESC has retained the
description in original morphofunctional categories withGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382further subclassiﬁcation into genetic (familial) and nonge-
netic (nonfamilial) groups. Both classiﬁcations continue to
exclude speciﬁc heart muscle disease (resulting from coro-
nary, hypertensive, valvular, and congenital heart disease)
from consideration as a cardiomyopathic disorder.
There is no denying the fact that most cardiomyopathies
are genetic diseases, which in the real life are brought to
clinical attention (and diagnosed and managed) based on a
phenotypic diagnosis. More than 60 disease genes have been
identiﬁed to date [9]; genes such as MYBPC3may be associ-
ated with different phenotypes (HCM, RCM, DCM), and
genes such as DYS may cause a unique phenotype (DCM
only). The penetrance of the genetic mutation is variable, and
phenotypic manifestations are often age dependent. Most
genetic cardiomyopathies are inherited as autosomal domi-
nant traits, with a minority of families demonstrating auto-
somal recessive, X-linked recessive or dominant (rare), and
matrilineal inheritance. Cascade family screening and follow-
up have become mandatory [10]. It has become necessary
for a more descriptive nosology to be developed that
may encompass either all attributes of the individual
patient cardiomyopathy or allow a common platform for
collaborative research efforts. A number of experts, including
clinical cardiologists, heart failureetransplantation physi-
cians, geneticists, and cardiovascular imagers, have proposed
a systematic nomenclature endorsed by the WHF Scientiﬁc
Committee. The proposed classiﬁcation is a descriptive
presentation of the cardiomyopathic process, which is ﬂex-
ibly modiﬁable and expandable. This nosology is inspired
from the TNM staging of tumors and is being simultaneously
published by the Journal of the American College of Cardiology
and the ofﬁcial journal of the WHF, Global Heart.The AHA (2006) classiﬁcation
In 2006, a scientiﬁc statement from the AHA redeﬁned
cardiomyopathy as a heterogeneous group of diseases of
myocardium associated with mechanical and/or electrical
dysfunction, which usually (but not invariably) exhibit
inappropriate ventricular hypertrophy or dilation, due to a
variety of causes that frequently are genetic [7]. The eti-
ology of some cardiomyopathies originally classiﬁed as355
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CC BY-NC-ND license.idiopathic or primary cardiomyopathy, or heart muscle
disease of unknown cause had become known, and there-
fore, such entities could not be described as idiopathic any
further. In the AHA 2006 deﬁnition, primary cardiomyopathy
referred solely or predominantly to the involvement of
heart; the primary cardiomyopathy designation in the new
deﬁnition did not mean diseases of myocardium associated
with myocardial dysfunction as intended in the 1996 WHO-
ISFC classiﬁcation. The secondary cardiomyopathy in the
AHA classiﬁcation was applicable when the myocardial
dysfunction was part of a systemic process. The proposed
classiﬁcation is reproduced in Figure 1A. Myocardial
dysfunction resulting from or associated with coronary,
hypertensive, valvular, or congenital heart disease was not
classiﬁed as cardiomyopathy. The WHF writing group ap-
plauds the efforts of the AHA 2006writing committee for theB
A
FIGURE 1. Current Classiﬁcations Of Cardiomyopathies. The
genetics-based classiﬁcation (A). On the other hand, the 2008
the morphofunctional phenotype and then the addition of inh
ventricular cardiomyopathy/dysplasia; CVPT ¼ catecholamin
cardiomyopathy; HCM ¼ hypertrophic cardiomyopathy; LV
syndrome; RCM ¼ restrictive cardiomyopathy; SQTS ¼ shor
death syndrome.ﬁrst genuine attempt to introduce a genetic basis of classi-
ﬁcation of cardiomyopathies.The ESC (2008) classiﬁcation
Although recognizing the necessity for identifying the
causative genetic defect as proposed by AHA (2006)
nomenclature, the ESC classiﬁcation emphasized that
because the morphofunctional phenotype was the basis of
the management of cardiomyopathy, it must also continue
to be the basis of classiﬁcation. ESC panelists emphasized
that some of the so-called primary cardiomyopathies may
be associated with extracardiac manifestations and may not
justify the primary cardiomyopathy designation. Similarly,
so-called secondary cardiomyopathy may occasionally
involve the heart predominantly and defy designation as2006 American Heart Association classiﬁcation proposes
European Society of Cardiology classiﬁcation suggests ﬁrst
eritance information (B). ARVC/D ¼ arrhythmogenic right
ergic polymorphic ventricular tachycardia; DCM ¼ dilated
NC ¼ left ventricular noncompaction; LQTS ¼ long QT
t QT syndrome; SUNDS ¼ sudden unexplained nocturnal
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secondary cardiomyopathy [8]. In the ESC classiﬁcation,
cardiomyopathy was deﬁned as a myocardial disorder in
which the heart muscle is structurally and functionally
abnormal. Cardiomyopathy was grouped into morpho-
functional phenotypes relevant for day-to-day clinical
practice. These included dilated, hypertrophic, restrictive,
and arrhythmogenic right ventricular cardiomyopathy and
unclassiﬁed variety. Each of these types was further divided
into familial genetic and nonfamilial, nongenetic forms. Ion
channelopathies, a genetic subtype included in the AHA clas-
siﬁcation of primary cardiomyopathy, was not accepted as
cardiomyopathy in this classiﬁcation because genes encoding
for ion channels might not result in morphofunctional phe-
notypes. However, similar to the AHA classiﬁcation, myocar-
dial dysfunction secondary to coronary, hypertensive, valvular,
or congenital heart disease was not considered as cardiomy-
opathy. In the ESC 2008 classiﬁcation, the cardiomyopathy
was deﬁned as familial when present inmore than 1member
of the family. A genetic cardiomyopathy is sporadic when the
causative mutation is de novo, namely occurring for the ﬁrst
time and exclusively in the affected family member. The pro-
posed classiﬁcation is reproduced in Figure 1B.The proposed phenotype-genotype-based (2013)
classiﬁcation endorsed by WHF
In the last 10 years, knowledge of the genetics of cardio-
myopathies has evolved exponentially, and at least 60 dis-
ease genes have been either conﬁrmed or suspected as
candidate genes (Table 1). The genetic heterogeneity is
established, and the implementation of next-generation
sequencing is further expected to increase the existing pool
of knowledge. It is conceivable that although the diagnosis
based on phenotype is still clinically useful, it is not sufﬁcient
to stratify prognosis in cardiomyopathies caused by muta-
tions in different genes and that grouping cardiomyopathies
per disease gene provides the basis for implementation of
disease-speciﬁc research. The major clinical decisions (such
as implantable cardioverter-deﬁbrillator [ICD] implanta-
tion) are still based on functional (such as left ventricular
[LV] ejection fraction [LVEF] in DCM) or morphological
(such as maximal LV wall thickness in HCM) criteria
regardless of the intrinsic disease risk related to the type of
causative gene mutation [11e13]. Troponinopathies may
not be associated with severe LV wall thickness but carry a
high arrhythmogenic potential [14]. Similarly, lam-
inopathies may not necessarily demonstrate severe LV
dysfunction when their arrhythmogenic risk ﬁrst manifests
[15]. On the other hand, dystrophinopathies may display
dramatically enlarged and dysfunctioning LV but are less
susceptible to the risk of malignant arrhythmias; such pa-
tients, however, can deteriorate rather precipitously with as
small an insult as a ﬂu episode and deserve timely assistance
[16]. Based on the underlying gene mutations, numerous
new terms (such as desmosomalopathies [17], cytoskeletalo-
pathies [18], sarcomyopathies [18], channelopathies [19], car-
diodystrophinopathies [16], or cardiolaminopathies [20]),GLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382inspired by the general practice of myologists (such as zas-
popathies [21], myotilinopathies [22], dystrophinopathies [23],
alphaB-crystallinopathies [21], desminopathies [24], or cav-
eolinopathies [25]), are being proposed that are likely to cloud
the cardiomyopathy description, and it has become impor-
tant that a uniform nomenclature be developed.
By the classiﬁcation herein proposed, the cardiomy-
opathies are described as disorders characterized by
morphologically and functionally abnormal myocardium
in the absence of any other disease that is sufﬁcient, by
itself, to cause the observed phenotype. In this nosology,
although the conventional phenotypic subtype of the car-
diomyopathy (e.g., dilated, hypertrophic) continues to
provide the elements for the basic classiﬁcation, a
genotype-based assessment dictates the diagnostic work-up
and treatment decisions in probands and relatives, as well
as the follow-up plans. Figure 2 shows an example of the
impact of an accurate genetic diagnosis on 2 patients with a
similar phenotype at presentation. Once the genetic cause
of the cardiomyopathy has been deﬁned, the cascade
family screening can help identify healthy mutation carriers
that will eventually develop the phenotype over the
ensuing years (Fig. 3) [10]. Avoidance of competitive sport
activity and tailored monitoring with early medical treat-
ment may favorably inﬂuence the natural history of the
disease and the development of the manifest phenotype, as
well as the risk of life-threatening arrhythmias. Identiﬁca-
tion of genetic diseases may also help subjects and alert
physicians to refrain from the use of injurious agents. For
instance, agents triggering malignant hyperthermia (succi-
nyl choline) or volatile anesthetics (halothane and iso-
ﬂurane) are to be avoided in emerinopathies and
laminopathies causing muscular dystrophy [26]. Statins
should be administered with caution in patients with ge-
netic cardiomyopathies with possible involvement of the
skeletal muscle, even when markers of myopathy are
negative [27]. Patients with disorders of the respiratory
chain may need surgeries in their long-term care, but an-
esthetics may interfere with metabolism and may trigger
unexpected complications [28]. Patients with mitochon-
drial cardiomyopathy and epilepsy should not receive
valproate because it could cause pseudoatrophy of brain
[29]. Common indications for heart transplantation (HTx)
in patients with end-stage cardiomyopathy should take
into account the speciﬁc diagnosis; conditions such as
Danon disease in males, or other comorbidities such as
mental retardation, are a matter of debate about indications
for HTx [30]. Finally, genotype-based diagnoses can be
pooled in large international databases for future clinical
trials and validation of novel management strategies.THE MOGE(S) NOMENCLATURE SYSTEM
While waiting for the complete knowledge that may
eventually support a genetic classiﬁcation of cardiomyop-
athies (also the ultimate intent of the AHA and ESC clas-
siﬁcations), we propose a nosology that addresses 5 simple357
TABLE 1. List of Nuclear Genes Associated to Date With Cardiomyopathies
Nuclear Genes
MIM*
Gene Protein or Syndrome HCM RCM DCM ARVC LVNC
Clinical Traits
(Red Flags)
Phenotypes/Diseases Caused by
Mutations of the Same Gene Inheritance
ABCC9 601439 ATP-binding cassette,
subfamily C, member 9
X Hypertricosis Cantu syndrome AD
ABLIM1 602330 Limatin (actin-binding LIM
domain protein)
X LVNC AD
ACTC1 102540 Cardiac actin alpha X X X X Nemaline myopathy AD
ACTN2 102573 Alpha-actinin 2 X X AD
ALMS1 606844 ALMS1-C X (70% DCM) Alstrom syndrome AR
ANO5 608662 Anoctamin 5 X Dysphagia Limb girdle muscular dystrophy,
Gnathodiaphyseal dysplasia,
Miyoshi muscular dystrophy 3
AR
ANKRD1 609599 Ankyrin repeat domain-
containing protein 1
X AD
BAG3 603883 BCL2-associated athanogene X X BAG3-related myoﬁbrillar myopathy,
CRYAB-related myoﬁbrillar
myopathy, fatal infantile
hypertrophy
AD
CALR3 611414 Calretinin 3 X AD
CASQ2 114251 Calsequestrin 2 X X AD
CAV3 601253 Caveolin3 X X sCPK elevated; long QT syndrome-9;
muscular dystrophy, limb-girdle;
myopathy, distal, Tateyama type;
rippling muscle disease
CRYAB 123590 Alpha B crystallin X X X Cataract Posterior polar cataract AD
CSRP3 600824 Cysteine- and glycine-rich
protein 3
X X AD
DES 125660 Desmin X X X AVB, [sCPK Des-related myoﬁbrillar myopathy,
neurogenic scapuloperoneal
syndrome, Kaeser type
AD
DMD 300377 Dystrophin X >sCPK/myopathy Duchenne muscular dystrophy,
Becker muscle dystrophy
X-linked
recessive
DMPK 605377 Dystrophia myotonica protein
kinase gene
X AVB (Dystrophia myotonica type 1) or
Steinert’s disease
AD
DOLK 610746 Dolichol kinase X Myopathy, possible
ichthyosiform
dermatitis
Congenital disorder of glycosylation,
type Im
AR
DSC2 125645 Desmocollin 2 X X With and without mild palmoplantar
keratoderma and woolly hair
AD
DSG2 125671 Desmoglein 2 X X AD
DSP 125647 Desmoplakin X X Lethal acantholytic epidermolysis
bullosa, keratosis palmoplantaris
striata II, skin fragilityewoolly
hair syndrome
AD
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DTNA 601239 Dystrobrevin alpha X With or without congenital heart
defects
AD
EMD 300384 Emerin X AVB, myopathy,
[sCPK
EDMD1, X-linked X-linked
recessive
EYA4 603550 Eyes absent 4 X Deafness Deafness, autosomal dominant AD
FHL1 300163 Four-and-a-half LIM domains 1 X X Myopathy EMDM 6, X-linked, myopathy,
reducing body, childhood-onset
and severe early-onset, myopathy
with postural muscle atrophy,
scapuloperoneal myopathy,
X-linked dominant
X-linked
recessive,
X-linked
dominant
GATAD1 614518 GATA zinc ﬁnger domain
containing protein 1
X AD
ILK 602366 Integrin-linked kinase X AD
JUP (DP3) 173325 Plakoglobin, desmoplakin III X X Naxos traits AD, AR
LMNA 150330 Lamin A/C X X AVB, possible [sCPK DCM with conduction disease plus
11 additional phenotypes
AD
LAMA4 600133 Laminin alpha 4 X AD
LDB3 605906 LIM domain-binding 3 X X X LVNC,
hypertrabeculation;
possible [sCPK
ZASP-related myoﬁbrillar myopathy AD
MYBPC3 600958 Myosin-binding protein C X X X AD
MYH6 160710 Alpha-myosin heavy chain 6 X X Atrial septal defect, sick sinus syndrome AD
MYH7 160760 Beta-myosin heavy chain 7 X X X X Possible [sCPK Laing distal myopathy; myosin storage
myopathy; scapuloperoneal
syndrome, myopathic type
AD
MYL2 160781 Myosin light chain 2 X AD
MYL3 160790 Myosin light chain 3 X X AD, AR
MYOZ1 605603 Myozenin 1 X X AD
MYOZ2 605602 Myozenin 2 X AD
MYPN 608517 Myopalladin X AD
NEBL 605491 Nebulette X AD
NKX2-5 600584 NK2 homeobox 5; cardiac-speciﬁc
homeobox1
X Possible conduction
system disease
AD
PDLIM3 605889 PDZ LIM domain protein 3 X AD
PLN 172405 Phospholamban X AR
PKP2 602861 Plakophilin 2 X X AD
PSEN1 104311 Presenilin 1 X Acne inversa, familial, 3, Alzheimer
disease, type 3, Frontotemporal
dementia, Pick disease
AD
PSEN2 600759 Presenilin 2 X Alzheimer disease AD
RBM20 613171 RNA-binding protein 20 X AD
RYR2 180902 Ryanodine receptor 2 X Ventricular tachycardia,
catecholaminergic
polymorphic 1
AD
(continued)
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TABLE 1. Continued
Nuclear Genes
MIM*
Gene Protein or Syndrome HCM RCM DCM ARVC LVNC
Clinical Traits
(Red Flags)
Phenotypes/Diseases Caused by
Mutations of the Same Gene Inheritance
SCN5A 600163 Sodium channel, voltage gated,
type V, alpha subunit
X Possible LQT or Brugada
Syndrome
LQT3, Brugada 1, AF, SSS, familial VF AD
SGCD 601411 Delta-sarcoglycan X Limb-girdle muscular dystrophy AD
SYNE1 608441 Nesprin 1, synaptic nuclear
envelop protein 1
X EMD4, AD; Spinocerebellar ataxia,
autosomal recessive
AD
TCAP 604488 Titin-cap; telethonin X X [sCPK Muscular dystrophy, limb-girdle,
type 2G
AD
TCF21 603306 Transcription factor 21, epicardin X Hearing loss Hearing loss AD
TGFB3 190230 Transforming growth factor beta-3 X X AD
TMEM43 612048 Transmembrane domain 43 X X Emery-Dreifuss muscular
dystrophy, AD
AD
TMPO 188380 Thymopoietin X AD
TNNC1 191040 Cardiac troponin C1 X X X AD
TNNI3 191044 Cardiac troponin I3 X X X AD
TNNT2 191045 Cardiac troponin T2 X X X X AD
TPM1 191010 Tropomyosin 1 X X X AD
TTN 188840 Titin X X Limb-girdle muscular dystrophy,
early-onset myopathy with fatal
cardiomyopathy, proximal
myopathy with early respiratory
muscle involvement, tardive tibial
muscular dystrophy
AD
VCL 193065 Vinculin X X AD
AD ¼ autosomal dominant; AF ¼ atrial ﬁbrillation; AR ¼ autosomal recessive; ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; AVB ¼ atrioventricular block; DCM ¼ dilated cardiomyopathy; HCM ¼
hypertrophic cardiomyopathy; LVNC ¼ left ventricular noncompaction; LQT ¼ long QT; MIM ¼ Mendelian Inheritance in Man; RCN ¼ restrictive cardiomyopathy; sCPK ¼ serum creatine phosphokinase; SSS ¼ sick
sinus syndrome; VF ¼ ventricular ﬁbrillation.
*Also reported in Table 3 listing mitochondrial disorders.
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FIGURE 2. Importance of Genetic Information in DCM
Patients. Two pedigrees with probands (arrows)
demonstrate similar DCM phenotypes at the onset of
disease. The identiﬁcation of the causative genes and
mutations underscores the importance of the genetic
diagnosis on the management of the 2 families (A,B). In
family A, the identiﬁcation of a mutation in the Emerin
(EMD) gene provides information about the genetic
status of the offspring (C). The son of the proband is
obligate negative because a male cannot transmit an
X-linked defect to his son. On the other hand, the
daughters of affected males in X-linked diseases are
obligate carriers of the paternal mutations. (D) In family
B, the identiﬁcation of a mutation in the Lamin A/C
(LMNA) gene provides evidence that offspring can
inherit the mutation with 50% probability for each
pregnancy (D). In this family in the right panel, both
children inherited the paternal mutation (þ). Pedigree
symbols for this and subsequent ﬁgures: circles for fe-
males, squares for males, diagonal lines represent
deceased, solid-dark gray symbols denote cardiomyop-
athy, dotted circles denotes healthy carriers. AD ¼
autosomal dominant; AVB ¼ atrioventricular block;
DCM ¼ dilated cardiomyopathy; ECG ¼ electrocardio-
gram; EF¼ ejection fraction; LVEDD ¼ left ventricular end-
diastolic dimension; NYHA ¼ New York Heart Association;
PM ¼ pacemaker; sCPK ¼ serum creatine phosphokinase;
SD ¼ sudden death; TAPSE ¼ tricuspid annular plane sys-
tolic excursion; XLR ¼ X-linked recessive.
FIGURE 3. Genotype, DCM, and the Natural History. In
1994, a patient underwent heart transplantation (HTx)
(arrow) for end-stage DCM associated with AVB. The
patient had received a pacemaker 4 years earlier. His
mother had died of heart failure due to DCM, and AVB
was treated with pacemaker implantation. In 2001, the
LMNA gene was discovered and was found to be the
etiology of cardiomyopathy in this family with DCM and
conduction disease. The cascade family screening further
uncovered 2 sons of the proband and the daughter of his
sister as the healthy mutation carriers. In 2004, the sister
of the proband underwent HTx for DCM and AVB, and in
2012, the oldest son of the proband was diagnosed with
early DCM. This 18-year-long follow-up highlights the
importance of genetic characterization in cardiomyopathic
disorders. Abbreviations as in Figure 2.
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December 2013: 355-382attributes of a cardiomyopathic disorder, including mor-
phofunctional characteristic (M), organ involvement (O),
genetic or familial inheritance pattern (G), and an explicit
etiological annotation (E) with details of genetic defect or
underlying disease/cause; information about the functional
status (S) using the American College of Cardiology/
American Heart Association (ACC/AHA) (A to D) stage and
New York Heart Association (NYHA) (I to IV) functional
classes may also be added. The addition of (S) has been left361
j gRECS
362optional, and should be used at the discretion of the
physician. With the description of 5 attributes, the classi-
ﬁcation system is designated as MOGE(S).
 The morphofunctional (M) notation provides a
descriptive diagnosis of the phenotype (MD ¼ dilated
cardiomyopathy; MH ¼ hypertrophic cardiomyo-
pathy; MA ¼ arrhythmogenic right ventricular (RV)
cardiomyopathy; MR ¼ restrictive cardiomyopathy;
MLVNC ¼ LV noncompaction). Description of combined/
overlapping phenotypes (MDþR or MHþD) is easy to
document, and disease-speciﬁc clinical markers can also
be added, such as atrioventricular block (AVB), Wolff-
Parkinson-White syndrome (WPW), epsilon wave (MD
[AVB], MH[WPW], MA[εwave]). Although not likely,
myocardial dysfunction with a nonspeciﬁc phenotype
may be mentioned (MNS). Early involvement or no
involvement in a mutation carrier with affected family
members should be documented as either with early
imaging markers (ME[H] or ME[D]) or unaffected (M0)
with the expected cardiac phenotype in brackets. When
the information about the morphofunctional cardiac
phenotype is not available (for example, in deceased
relatives), the description is MNA[H].
 The organ involvement (O) is documented as heart
only (OH) or involvement of other organs/systems as
below. The extracardiac involvement may be described
by organ/system notations, such as skeletal muscle
(OHþM), auditory system (OHþA), kidney (OHþK), nervous
system (OHþN), liver (OHþL), gastrointestinal system
(OHþG), cutaneous (OHþC), eye, ocular system (OHþE), or
OHþMR for mental retardation. Involvement of other or-
gans may represent the systemic disease. Healthy mu-
tation carriers can be described as (O0), because the
heart is not yet involved.
 The genetic or familial inheritance (G) provides in-
formation about autosomal dominant (GAD), autosomal
recessive (GAR), X-linked (GXL), X-linked recessive (GXLR),
X-linked dominant (GXLD), or matrilineal (GM) trans-
mission. GXL could also be used without recessive
or dominant speciﬁcation for conditions when an X-
linked inheritance is strongly suspected on the basis of
pedigree and family screening but is not yet supported
by results of genetic testing and should be clariﬁed in the
E notation. Sporadic (GS) indicates only a nonfamilial
disease or a disease present in one family member when
information or data on other family members are not
(and will not be) available. Sporadic (GS) notation is also
applied in cases with possible de novo mutation not yet
identiﬁed. GN indicates negative family history, and GU
indicates unknown family history. G0 indicates that
family history has not been investigated so far.
 The etiological annotation (E) adds to the description
of the underlying cause. For instance, genetic (EG) eti-
ology can be described by the speciﬁc disease gene and
mutation(s) such as in the case of HCM (EG-MYH7
[p. Arg403Glu]), or familial amyloidosis (EA-TTR[p.Val122Ile]),and so on. Etiological speciﬁcation may include:
noncarrier (EG-Neg) when the disease gene tested nega-
tive; obligate carrier (EG-OC); obligate noncarrier (EG-ONC);
presence of more than 1 mutation (or complex genetic
defects, EG-C wherein all genetic information should be
documented); genetic test not available yet, but the
family data clearly indicate a genetic disease or the test is
ongoing (EG-NA); genetically orphan patients after
completion of the screening of all known disease genes
in familial disease (EG-N); or genetic testing is not done or
not feasible for any reason (EG-0). All above may facilitate
description of mutations that do not segregate with the
phenotype or incomplete genotyping. Please see speciﬁc
examples in the individual cardiomyopathy sections in
the following text and in Figures 2 to 10.
On the other hand, the nongenetic etiology can be
described as viral (V) adding the virus (e.g., Coxsackie B3
virus [CB3], human cytomegalovirus [HCMV], Epstein-
Barr virus [EBV]) as (EV-HCMV), (EV-CB3) or (EV-EBV).
Similarly, infectious nonviral disease can be described as (EI)
with further speciﬁcation of the infectious agent when
possible. Myocarditis can be described as (EM) when the
myocarditis is the proven cause of the myocardial disease;
speciﬁcation about sarcoidosis or nonviral or noninfectious
giant cell myocarditis should be added (EM-sarcoidosis).
Autoimmune etiology, either suspected or proven, can be
added (EAI-S) or (EAI-P), respectively, after having excluded
genetic and viral or toxic causes, especially in patients in
whom a speciﬁc etiology may inﬂuence treatment. In the E
annotation, nongenetic amyloidosis (EA-K) or (EA-L) or
(EA-SAAA) should be described with kappa, lambda, serum
amyloid A, or other protein characterization. Toxic cardio-
myopathies, either endogenous such as pheochromocytoma-
related cardiomyopathy, or drug-induced cardiomyopathy,
are described (ET-Pheochromocytoma or ET-Chloroquine). The
eosinophilic Loefﬂer endomyocarditis can be described ac-
cording to the cause as either being idiopathic or a part of
myeloproliferative disorder associated with the somatic
chromosomal rearrangement of PDGFRa or PDGFRb genes
that generate a fusion gene encoding constitutively active
PDGFR tyrosine kinases. The E annotation will be modiﬁed
in the future as various conditions are excluded from the
category of cardiomyopathic disorders or as the newer en-
tities are recognized.
 It is proposed that Heart Failure Stage (S) may be
provided pertaining to ACC/AHA stage (A to D) and
NYHA functional class (I to IV) if deemed necessary. For
instance, stage A disease with functional class I can be
written as (SA-I) or stage C disease in functional class II
symptomatic subjects can be referred to as (SC-II).
Addition of the ﬁfth descriptor (S) is optional, but
may come in handy for the description of early cardio-
myopathy. Early cardiomyopathy is a condition where
the clinical criteria for diagnosis of the cardiomyopathy
are not present, but genetic mutation has been conﬁrmed
and/or subclinical imaging evidence of myocardialGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382
FIGURE 4. The MOGE(S) in a Family With HCM. The MOGE(S) system allows presentation of all essential clinical and
genetic information in a family with HCMand complex genetics.The pedigree shows the affected and nonaffected status of
family members and the mutations identiﬁed in the family. The table (bottom) shows the application of the MOGE(S)
system and the comprehensive description of the genetic make-up and phenotype expression in themembers of different
generations of the family. Although 3 mutations have been identiﬁed in this family, the HCM is inherited as autosomal
dominant disease, and themutation that occurs in all affectedmembers isMYH7 p.R663H; othermutationsmay contribute
to worsen the phenotype but do not seem to cause, by themselves, HCM. In families demonstrating autosomal dominant
inheritance, the segregation of the mutation from the phenotype is necessary to avoid labeling of the carriers of
nondeterministic gene variants as possible future patients, and to provide a correct interpretation of results in case of
prenatal diagnosis. Given the high prevalence of HCM in the general population (1:500), families carrying more than 1
mutation are not rare, and are expected to further increasewith next-generation sequencing (NGS), that allows sequencing
of several common and rare genes in a large number of patients simultaneously. AF¼ atrial ﬁbrillation; ICD¼ implantable
cardioverter-deﬁbrillator; IVS¼ Intervening sequence; other abbreviations as in Figure 2. Green ﬁlled symbols: mild LVH.
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FIGURE 5. MOGE(S) in a Family With Mitochondrial Cardiomyopathy: Evolution of the Disease in Family and Clari-
ﬁcation of the Genetic Basis of Disease During Follow-Up. The pedigree illustrates the case of a young boy who was
affected by mild mental retardation and bilateral coloboma. In 2007 he was ﬁrst diagnosed with HCM and Wolff-
Parkinson-White syndrome (WPW). His family history revealed the death of a maternal cousin at the age of 22
years for Duchenne muscular dystrophy (DMD). Based on family history and pedigree, the ﬁrst hypothesis was an X-
linked recessive disease, which was, however, unlikely because of the HCM phenotype, the WPW, and the mental
retardation. The DYS gene tested negative in the proband (both multiplex ligation-dependent probe ampliﬁcation
[MLPA] and sequencing) as well as in the mother and maternal grandmother whose sister was healthy carrier of DYS
mutation and mother of the young man with DMD. LAMP2 was analyzed because of the HCM phenotype with WPW
and cognitive impairment, and tested negative. Sequencing of the mitochondrial DNA (mtDNA) demonstrated the MT-
TL1 MELAS/LS A3243G mutation [tRNA Leu (UUR)], heteroplasmic in all maternal relatives and in the boy. Endomyo-
cardial biopsy was not performed. During the ensuing years, the patient showed worsening of HCM with evolution of
left ventricular (LV) dysfunction (LVEF ¼ 35%) and developed stroke-like episodes to result in death. The MOGE(S)
system summarizes the clinical and genetic status of the family in 2011 and the key clinical traits of the disease. LVH ¼
left ventricular hypertrophy; other abbreviations as in Figure 2.
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FIGURE 6. MOGE(S) in a Family With AFD. On the left side of the ﬁgure, the example of Anderson-Fabry disease (AFD)
highlights the importanceof family study anddemonstrates how simple is it to suspect the disease (left).The proband (arrow)
wasbrought tomedical attention for the clinical suspicionofHCM.The family history, however, revealed long-lastingmaternal
gastrointestinal disturbances (common diseases causing such disorders had been excluded), a stroke in the maternal aunt,
and renal failure in thematernalmale cousin. Further screening of the family uncovered cornea verticillata in themother and
angiokeratomas in themale cousin.The serial examination of urine samples in the proband showed intermittent proteinuria,
and the genetic testing conﬁrmed the diagnosis of AFD. The MOGE(S) ﬁgure only summarizes the last clinical and genetic
status of the family. Individual VI:1 is an obligate noncarrier, whereas individual I:1 (genetic test not performed) is an obligate
carrier because the wife tested negative and both daughters carried the mutation. If the genetic test were available in I:1, it
would not have been necessary in the daughters because both are naturally obligate carriers. In the right half of the ﬁgure,
from top to bottom, the pathological features of AFD in endomyocardial biopsy are shown. (A) Hematoxylin and eosin stain
shows a large number of vacuolated myocytes (glycosphingolipids are extracted in formalin-ﬁxed, parafﬁn-embedded tis-
sues); (B) the toluidine blue stain of the semi-thin sections from resin-embedded samples for electron microscopy show
characteristic intramyocyte accumulation of osmiophilic bodies of the storage material; and (C) the ultrastructural panel
conﬁrms the typical lamellar and dense osmiophilic bodies. Abbreviations as in Figures 2. Grey ﬁlled symbols: mild LVH.
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FIGURE 7. MOGE(S) in a Family With Danon Disease. The example of Danon disease caused by a mutation of the LAMP2
gene and the natural history of the disease in the family from 1986 to 2013; the family history of 27 years is summarized in
the table (bottom right). Although Danon disease in its typical presentation affects males (LAMP2 gene maps on the X
chromosome) who show HCM, myopathy, and mental retardation (see the table), the cardiac phenotype is expressed also
in adult female carriers who do not show myopathy and mental retardation. The II:3 male showed the typical phenotype;
his sister who had 3 pregnancies and 3 prenatal diagnoses is now affected by cardiomyopathy. Her second pregnancy (a
male fetus and a positive genetic test) ended in a voluntary interruption, whereas the third pregnancy (female fetus and
positive genetic testing) ended in a Cesarean section due to worsening of ventricular arrhythmias during pregnancy. The
girl is now well with normal electrocardiographic and echocardiographic features.The chromatogram shows the mutation
identiﬁed in the LAMP2 gene in I:2. Abbreviations as in Figure 2.
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FIGURE 8. MOGE(S) in RCM With Cardiac Desminopathy and Intramyocyte Storage of Desmin. Typical cardiac des-
minopathies with intramyocyte desmin accumulation are clinically characterized by RCM and AVB; the family history is
presented in left panel and the typical pathologic features of the myocardium in the right panel. Individual I:1 un-
derwent heart transplantation (HTx), as did her son II:3. The other 2 affected sons died of heart failure after diagnosis of
RCM and pacemaker implantation. After transplantation II:3 married the unrelated II:4 (shown in blue letters in the
MOGE, 2013 table) who also underwent HTx for DCM. II:4 had undergone HTx without family screening with a pre-
sumptive diagnosis of post-myocarditic DCM. However, her heart excised at transplantation did not show features of
myocarditis, and the viral genome search was negative. The couple (II:3 and II:4) had a boy (III:1) in which the paternal
DES mutation was excluded. However, in case the viral etiology of the DCM was wrong and the mother had a genetic
DCM, the genetic status of the boy (although DES mutation is ruled out) remains incomplete, and the risk of developing
DCM is unknown. The right panel shows (A) hematoxylin and eosinestained myocardial samples in desminopathy. The
eosinophilic bodies correspond to the accumulation of desmin, and myoﬁbrillar disarray is present. (B) Anti-desmin
immunostaining supports the diagnosis but remains nonconclusive in light microscopy study due to the variable
orientation of myocytes in small EMB samples with procedure-related contraction bands. (C) Electron microscopy study
is the gold standard for the pathological diagnosis. Abbreviations as in Figure 2.
gRECSjinvolvement is apparent. The imaging alterations may
include increased LV end-diastolic diameter and reduced
longitudinal strain with still normal ejection fraction (EF)
for DCM, or borderline LV thickening for HCM. TheGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382ACC/AHA guidelines include patients with a family his-
tory of cardiomyopathy in stage A. Therefore, the MOGE(S)
can take advantage of the stage to describe individuals
that show early markers of disease but do not fulﬁll the367
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FIGURE 9. MOGE(S) in Dilated Cardiac Dystrophinopathy. The ﬁgure presents 3 diagnostic steps in a family with X-linked
recessive DCMcaused bydeletionmutation of theDystrophin gene.The proband showed an apparently sporadic DCMwith
severely dilated left ventricle and decreased EF; the presence of increased sCPK suggested the possibility of a Dystrophin
defect. The MLPA demonstrated an in-frame deletion of exons 45 to 48. The noncarrier sister at her ﬁrst pregnancy asked
about private umbilical blood cord preservation for future stem cell (SC) transplantation in the affected brother. This
request is increasing in Dystrophin families and, at present, regulatory bodies and scientiﬁc societies in different countries
do not provide uniform recommendations.We realize that a deﬁnite donor cell engraftment is not yet proven, and such a
request should only be considered in consultation with SC transplantation experts and specialized centers; private SC
preservation with costs covered by the family is feasible.The family study documented the carrier status of themother and
of 1 of the sisters (II:3). Bottom: the myocardial pathology shows that the Dystrophin defect is associated with decreased
expression of the protein (B) as compared to abundant expression (A) in a normal heart. A represents an endomyocardial
biopsy specimen obtained from a donor heart before transplantation. Abbreviations as in Figure 2.
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FIGURE 10. MOGE(S) in Barth Syndrome. The ﬁgure shows the case of a boy who demonstrated a severe and rapidly
fatal neonatal dilated cardiomyopathy. The family history was negative: both parents were healthy, and there were no
relatives affected by cardiac diseases. The presence of LVNC suggested the possibility of Barth syndrome. The genetic
testing showed a hemizygous mutation in the G.4.5 gene encoding the nuclear mitochondrial protein tafazzin. The
mutation was inherited from the healthy mother whose clinical screening demonstrated a normal heart. At the second
pregnancy, the prenatal diagnosis demonstrated a male fetus carrier of the mutation. The pregnancy was interrupted. At
the third pregnancy, the prenatal diagnosis showed the male fetus a noncarrier of the mutation. The pregnancy was
successful, and the boy is healthy. The mother did not show cardiac problems during or after the 3 pregnancies. Ab-
breviations as in Figure 2.
gRECSjdiagnostic criteria for the cardiomyopathy. In families
with known mutation, the diagnosis of early cardiomy-
opathies can be further supported by the presence of the
mutation(s), whereas in genetically orphan familial car-
diomyopathies, only the early imaging markers of the
disease can be highlighted. This description could be
especially useful for sport worthiness that often requires
physicians to provide a deﬁnitive recommendation, and
(S) notationmay allow the description of a gray diagnosticGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382zone. Although criteria for early diagnosis of cardiomy-
opathy are not systematically described, the increasing
family screening and monitoring have revealed that the
cardiomyopathies likely serve a long pre-clinical
or subclinical interval before the onset of symptoms or the
manifestation of the clinical phenotype [31].
Table 2 shows the MOGE(S) system notations and
modeling. The alphabetical components are likely going to369
TABLE 2. The MOGE(S) Nomenclature: Some Common Examples Are Provided in the Lower Part of the Table
M
Morphofunctional Phenotype*
O
Organ/System Involvementy
G
Geneticz
E
Etiological Annotationx
S
Stage; ACC/AHA Stage,
NYHA Functional Classk
(D) Dilated
(H) Hypertrophic
(R) Restrictive
(A) ARVC
(NC) LVNC
Overlapping (HþR),
(DþA), (NCþH),
(HþD), (DþNC) or
more complex
combinations such as
(HþRþNC)
(E) Early, with type
in parentheses
(NS) Nonspeciﬁc
phenotype
(NA) Information
not available
(0) Unaffected
(H) Heart
(M) Muscle, skeletal
(N) Nervous
(C) Cutaneous
(E) Eye
(A) Auditory
(K) Kidney
(G) Gastrointestinal
(S) Skeletal
(0) Absence of organ/
system involvement, e.g.,
in family members who
are healthy mutation
carriers; the mutation
is speciﬁed in E and
inheritance in G
(N) Family history negative
(U) Family history unknown
(AD) Autosomal dominant
(AR) Autosomal recessive
(XLR) X-linked recessive
(XLD) X-linked dominant
(XL) X-linked
(M) Matrilineal
(DN) De novo
(0) Family history not
investigated
(G) Genetic etiology—add gene and mutation; (NC)
Individual noncarrier plus the gene that tested
negative
(OC) Obligate carrier
(ONC) Obligate noncarrier
(DN) De novo
(C) Complex genetics when >1 mutation (provide
additional gene and mutation)
(Neg) Genetic test negative for the known familial
mutation
(NA) Genetic test not yet available
(N) Genetic defect not identiﬁed
(0) No genetic test, any reason (no blood sample, no
informed consent, etc.)
Genetic amyloidosis (A-TTR) or hemochromatosis (HFE)
Nongenetic etiologies:
(M) Myocarditis
(V) Viral infection (add the virus identiﬁed in affected
heart)
(AI) Autoimmune/immune-mediated; suspected (AI-S),
proven (AI-P);
(A) Amyloidosis (add type of amyloidosis: A-K; A-L,
A-SAA)
(I) Infectious, nonviral (add the infectious agent)
(T) Toxicity (add toxic cause/drug)
(Eo) Hypereosinophilic heart disease
ACC/AHA stage
represented as
letter (A, B, C, D)
To be followed by
NYHA functional class
represented in Roman
numerals (I, II, III, IV)
MD, MH, MR, MA, MNC,
M0, MHþR, MDþA
OH, OM, OK, OC GN, GU, GAD, GAR, GXLR,
GXLD, GXD, GM, GDN
EG-MYH7[R403E], EG-HFE[Cys282Tyrþ/þ],
EV-HCMV, EG-A-TTR[V30M], EM-sarcoidosis
SA-I, SA-II
ACC/AHA ¼ American College of CardiologyeAmerican Heart Association; NYHA ¼ New York Heart Association; other abbreviations as in Table 1.
*The morphofunctional phenotype description (M) may contain more information using standard abbreviations, such as AVB ¼ atrioventricular block; WPW ¼Wolff-Parkinson-White syndrome; LQT ¼ prolongation
of the QT interval; AF ¼ atrial ﬁbrillation; YR ¼ low electrocardiogram voltages; YPR ¼ short PR interval.
yOrgan (O) involvement in addition to the H subscript (for heart) should be expanded for the involvement of M ¼ skeletal muscle, E ¼ eye, ocular system, A ¼ auditory system, K ¼ kidney, L ¼ liver, N ¼ nervous
system, C ¼ cutaneous, G ¼ gastrointestinal system, and other comorbidities, including MR ¼ mental retardation.
zGenetic (G) describes the available information about inheritance of the disease. It also provides complete information if the family history is not proven or unknown, and if genetic testing has not been performed
or was negative for the mutation/mutations identiﬁed in the family.
xThe etiologic annotation (E) provides the facility for the synthetic description of the speciﬁc disease gene and mutation, as well as description of nongenetic etiology.
kThe functional annotation or staging (S) allows the addition of ACC/AHA stage and NYHA functional class.
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change in parallel with new scientiﬁc discoveries. As
anticipated, the proposed nosology is modeled similarly to
the universally accepted TNM staging of tumors, which has
been consistently expanded and has allowed use of a
common language of clinical comprehension and utility
[32]. In TNM staging, the T describes the size of carci-
noma and extent of local invasiveness, N stands for the
status of lymph nodes, and M provides for the presence or
absence of metastases. There are additional descriptors; for
instance, the preﬁx y with T indicates that the cancer was
resected after neoadjuvant therapy, r indicates recurrence
of cancer, and m identiﬁes multifocal cancer. Similarly the
nodal status can be iD (isolated tumor cells), mic
(micrometastatic, 0.2 to 2.0 mm), or mac (macro-
metastases, >2 mm). The clinical staging is designated as
cTNM and the pathological staging of cancer as pTNM.
In the MOGE(S) nomenclature, ion channelopathies
are not included, but can be incorporated if so needed in
the future. The reason for the exclusion is that due to the
high prevalence of genetic variations in ion channel genes
and the ever-increasing genetic complexity of cardiomy-
opathy, it cannot be excluded that few available reports of
ion channel mutations in patients with cardiomyopathy (in
the absence of screening of all other disease genes) may in
fact represent an incomplete genotyping. In a series of
more than 100 DCM patients in whom the SCN5A gene
was screened along with other genes, a single mutation was
identiﬁed in 1 patient who was also carrier of the PLN
mutation [33]. The channelopathies are nosologically well-
deﬁned arrhythmogenic disorders [34] without LV
remodeling and with clinical needs that differ from those of
cardiomyopathies. Giving the large spectrum of electrical
phenotypes associated with mutations of ion channel
genes, this group of diseases likely deserves a speciﬁc and
independent nomenclature.The MOGE(S) nomenclature in the diagnostic
work-up of cardiomyopathies
It is expected that the clinical and imaging characterization
of the phenotype (M) would be routinely deﬁned on
morphological (dilated, hypertrophic, LV noncompaction
[LVNC]) and morphofunctional (restrictive, arrhythmo-
genic) traits, and the second descriptor (i.e., the organ
involvement, O) would require to specify whether the
heart is the only affected organ or other organs/systems are
involved (Table 2). The disease may be systemic and the
involvement of the heart a part of general disease process.
This simple deﬁnition of the involvement of the heart only,
of the heart as a component of systemic disease process,
and the involvement of other organs provides useful clin-
ically discriminatory information. The ﬁrst combination of
(M) and (O) can offer preliminary diagnostic clues. For
instance, MH OHþSMþMR suggests the possibility of HCM
in either Danon or mitochondrial DNAerelated disease;
when additional details are available, such as MH[WPW] OH,
a mutation of PRKAG2 might be suspected. Similar cluesGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382could be available for dilated cardiolaminopathy MD[AVB]
OH, dilated cardiodystrophinopathy MD[[sCPK] OHþM, or
restrictive desminopathy MR[AVB] OHþM and underscore
the importance of identifying clinical indicators (“red
ﬂags”) in the MOGE(S) nomenclature [35].
Data from family pedigrees, including investigation for
the family history and the pattern of inheritance (G), add
valuable leads for complete characterization of the cardio-
myopathy. For example, a restrictive cardiomyopathy with
autosomal dominant inheritance, but without conduction
disease and involvement of other organ systems, suggests
troponinopathy (MR OH GAD). Information about G may
help discriminate similar phenotypes: (MH[WPW] OH GAD)
might suggest an HCM associated with PRKAG2 mutation,
whereas (MH[WPW] OHþMþMR GXL) suggests Danon disease,
or (MH[WPW] OHþMþN GM) mitochondrial DNAerelated
cardiomyopathy. The etiological annotation (E) provides a
descriptive analysis of the genetic defect and/or underlying
disease. For nongenetic and nonfamilial cardiomyopathy,
the E annotation may include other etiologies.
Although it may seem a bit complex in the beginning,
this nomenclature does provide an articulated conﬁgura-
tion that is able to transmit all essential information for
every cardiomyopathy type, patient, and family; a genetic
tree and reference to family members per generation may
be appended when needed (Fig. 4). An easy web applica-
tion (app) for MOGE(S) nomeclature can be accessed from
mobile phones and other devices (http://moges.biomeris.
com). The app becomes handy for correct notation at
least in the initial stages. The abbreviations applied here
(such as AVB or WPW) are consistent with terminology
systems such as Systematized Nomenclature of Medicine
(SNOMED) [36] or SNOMED CT (SNOMED Clinical
Terms) [37] and in the International Classiﬁcation of Dis-
eases (ICD) [38]. The proposed nomenclature reﬂects the
diagnostic work-up of cardiomyopathies for evaluation of
the phenotype, implementation of family screening strate-
gies for diagnosis and prevention, and results of genetic
testing in the Sanger and post-Sanger era.MOGE(S) NOMENCLATURE FOR HCM
HCM phenotypically denotes a heterogeneous group of
syndromes all sharing a cardiac trait of thickening of the LV
wall; the 2 major groups include sarcomeric (up to 90% of
all HCM caused by mutations of structural and regulatory
genes of the sarcomere) and nonsarcomeric HCM (Table 1).
The diagnosis of sarcomeric HCM implies that a sar-
comeric gene defect has been identiﬁed, and the mutation
is duly noted in the etiological (E) annotation, such as MH
OH GAD EG-MYH7[p.Arg403Glu]. Although earlier studies
attempted to correlate distinct gene defects with the
severity of the disease, little has been conﬁrmed after 20
years of genotype to phenotype correlation studies [39].
Several disease genes have been identiﬁed; defects of MYH7
and MYBPC3 account for up to 70% of sarcomeric HCM,
followed by troponin gene defects (TNNI3, TNNT2) and371
TABLE 3. Major Mutations in MTDNA* and Nuclear Genes and Cardiac Phenotypes Reported to Date
MTDNA Disease Allele Gene HCM DCM RCM LVNC
MTTL1 MMC/MELAS A3260G tRNALeu(UUR) X X
MTTL1 MMC C3303T tRNALeu(UUR) X X
MTTL1 MELAS A3243G tRNALeu(UUR) X X X X
MTTL1 MELAS G3244A tRNALeu(UUR) X
MTTL1 MM/HCM þ RENAL TUBULAR
DYSFUNCTION
G3242A tRNALeu(UUR) X X
MTTL1 MELAS A3252G tRNALeu(UUR) X
MTTL1 MELAS/myopathy T3258C tRNALeu(UUR) X X
MTTL1 Myopathy A3280G tRNALeu(UUR) X X
MTTL2 DCM/LS/failure to thrive and LA T12297C tRNALeu(CUN) X
MTTI MHCM A4295G tRNAIle X X
MTTI MICM A4300G tRNAIle X X
MTTI FICP A4269G tRNAIle X X
MTTI HCM with hearing loss/possible
hypertension factor
A4316G tRNAIle X
MTTI FICP A4317G tRNAIle X X
MTTI Varied familial presentation/spastic
paraparesis
G4284A tRNAIle X X
MTTI Mitochondrial
encephalocardiomyopathy
C4320T tRNAIle X X
MTTK Cardiomyopathy/SNHL A8348G tRNALys X X
MTTK MERRF A8344G tRNALys X X
MTTK MERRF/MICMþDEAF/autism/LS G8363A tRNALys X X
MTTG MHCM T9997C tRNAGly X
MTTH MICM G12192A tRNAHis X
MTTP DCM T16032TTCTCTGTTCTTTCAT
(15 bp dup)
tRNAPro X
MTTQ Possibly LVNC-associated T4373C tRNA Gln X
MTTV LS C1624T tRNAVal X X
MTTV Adult LS G1644T tRNAVal X
MTRNR2 MELAS C3093G 16S rRNA X
MTRNR1 Possibly LVNC-associated T921C 12S rRNA X
MTRNR1 Possibly LVNC-associated T850C 12S rRNA X
MTRNR1 DEAF, possibly LVNC-associated T961C 12S rRNA X
MTRNR1 Found in 1 HCM patient T1391C 12S rRNA X
MTRNR1 Found in 1 HCM patient C1556T 12S rRNA X
MTRNR2 Possibly LVNC-associated T2352C 16S rRNA X
MTRNR2 Possibly LVNC-associated G2361A 16S rRNA X
MTRNR2 Possibly LVNC-associated A2755G 16S rRNA X
MTCYB HCM G15243A (G166E) MTCYB X
MTCYB HCM/WPW,DEAF G15498A (G251D) MTCYB X
MTCO1 Idiopathic sideroblastic anemia T6721C (M273T) MTCO1 X
MTCO1 Idiopathic sideroblastic anemia T6742C (I280T) MTCO1 X
MTND4 Diabetes mellitus A12026G (I423V) MTND4 X
(continued)
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372other less commonly involved genes (ACTC1, CSRP3,
CRYAB, CAV3, MYH6, MYL2, MYL, TNNC1, TCAP,
MYOZ1, MYOZ2) (Table 1). The extracardiac markers are
conspicuously absent in autosomal dominant sarcomeric
HCM. A minority of sarcomeric HCM may show associated
myopathy, a feature that may be described as MH OHþMGAD EG-MYH7[p.Arg403Glu]. Autosomal recessive HCM is rare
[40]: these families differ from those in which double or
triple mutations are identiﬁed but inheritance is autosomal
dominant. In fact, an increasingly greater proportion of
patients with sarcomeric HCM are being recognized with
double and compound mutations contributing to worseGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382
TABLE 3. Continued
Nuclear
Genes Phenotype Inheritance HCM DCM RCM LVNC
ANT1 (PEOA2) AD-PEO, multiple mtDNA deletions AD X X
AGK Sengers syndrome (HCM, cataract and myopathy) AR X
COX10 Neonatal tubulopathy and encephalopathy, LS AR X
COX15 Early-onset HCM, LS AR X
DNAJC19 DCM and LVNC, early onset, anemia, ataxia, male
genital anomalies and methylglutaconic aciduria
type V
AR X X
FRDA Friedreich ataxia, neuropathy, cardiomyopathy, diabetes AR X X
G4.5 (Tafazzin) Barth syndrome, X-linked dilated cardiomyopathy X-linked X X
MFN2 Charcot-Marie-Tooth disease type 2A2 AD X
POLG (PEOA1) Alpers syndrome, AD-PEO and AR-PEO, male infertility,
SANDO syndrome, SCAE
AD-AR X X
NDUFS2 Encephalopathy AR X X
NDUFV2 Hypotonia, encephalopathy AR X
SCO2 Neonatal cardio-encephalomyopathy AR X X
DEAF ¼ maternally inherited deafness or aminoglycoside-induced deafness; FICP ¼ fatal infantile cardiomyopathy plus, a MELAS-associated car-
diomyopathy; LD ¼ Leigh disease; LS ¼ Leigh syndrome; LA ¼ Lactic Acidosis; LVNC ¼ left ventricular noncompaction; MELAS ¼ mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF ¼ myoclonic epilepsy and ragged red muscle ﬁbers; MHCM ¼ maternally
inherited hypertrophic cardiomyopathy; MICM ¼ maternally inherited cardiomyopathy; MMC ¼ maternal myopathy and cardiomyopathy;
mtDNA ¼ mitochondrial DNA; PEO ¼ progressive external ophthalmoplegia; SANDO ¼ sensory ataxic neuropathy with dysarthria/dysphagia and
ophthalmoplegia; SCAE ¼ spinocerebellar ataxia with epilepsy; other abbreviations as in Table 1.
*http://www.mitomap.org; last accessed November 6, 2013. Short PR electrocardiogram intervals and pre-excitation recur in mitochondrial cardiac
phenotypes, especially in the early phases of the disease. Atrioventricular block is more common in late phases of the disease.
gRECSjphenotype and high arrhythmogenic risk regardless of the
ventricular wall thickness; double (or compound) muta-
tions detected by genetic testing may confer a genedose
effect in HCM (such as MH OH GAD EG-MYH7[p.Arg403Glu]þ
MYBPC3[IVS7þ1G>A]) and may predispose patients to adverse
disease progression [41,42]. Some examples of MOGE(S)
nomenclature for sarcomeric HCM are presented below.
MH OH GAD EG-MYH7[p. Arg403Glu] SB-I represents: mor-
phofunctional phenotype (M): hypertrophic (H) cardio-
myopathy; organ (O) involvement: heart (H); genetic/
familial (G) with autosomal dominant (AD) transmission;
etiology (E): genetic (G) and caused by the p.Arg403Glu
mutation of theMYH7 gene, ACC/AHA stage (S) B,NYHA I.
ME(H) OH GAD EG-MYH7[p. Arg403Glu] SA-I represents
morphofunctional phenotype (M): “early” (E) hypertro-
phic (H) cardiomyopathy (for example, borderline LV
thickness or early diastolic dysfunction or electrocardio-
graphic (ECG) abnormalities suggesting hypertrophy with
normal LV thickness); organ (O) involvement: heart (H);
genetic/familial (G) with autosomal dominant (AD)
transmission; etiology (E): genetic (G) and caused by the
p.Arg403Glu mutation of theMYH7 gene; ACC/AHA stage
(S) A, NYHA I.
ME(H) OH GAD EG-NA SA-I represents: morphofunc-
tional phenotype (M): “early” (E) hypertrophic (H) car-
diomyopathy organ (O) involvement: heart (H); genetic/
familial (G) with autosomal dominant (AD) transmission;
etiology (E): genetic but the mutation is not yet available
(NA) (either ongoing or to be done but feasible); ACC/
AHA stage (S) A, NYHA I.GLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382M0 O0 GAD EG-MYH7[p. Arg403Glu] SA-I represents:
morphofunctional phenotype (M): “unaffected” (0) by
cardiomyopathy; organ (O) involvement: absence of any
cardiac phenotype (zero, 0); in familial/genetic (G) auto-
somal dominant (AD) cardiomyopathy; etiology (E) ge-
netic (G), healthy carrier of the p.Arg403Glu mutation of
the MYH7 gene that causes the disease in the family; ACC/
AHA stage (S) A, NYHA I.
Because the intrafamily variability of the phenotype
may include different morphofunctional phenotypes (for
example, HCM and DCM, the latter often representing the
end-stage evolution of the original hypertrophic pheno-
type), a combination of morphofunctional phenotypes is
possible (HDD).
Nonsarcomeric HCM may show different types of in-
heritance, such as AD in PRKAG2-related HCM with WPW
[43], AR in Friedrich ataxia [44], X-linked in Danon dis-
ease [45] and in Anderson Fabry disease (AFD) [46], AR in
Pompe disease [47], or matrilineal (or maternal) in car-
diomyopathies caused by mutations in the mitochondrial
DNA [48,49] (Table 3, Fig. 5). Mitochondrial diseases
constitute a large and heterogeneous group of complex
diseases/syndromes (1 per 4,000 to 5,000 live births)
caused by mutations of nuclear (inherited according to
Mendelian rules) or mitochondrial (matrilineal inheritance
with absence of male transmission) genes. Cardiologists
encounter mitochondrial diseases in their routine practice
either in patients presenting with HCM or DCM, or in
patients referred by neurologists or myologists for
consultation. The role of the cardiologists is essential for373
TABLE 4. Most Common Metabolic Diseases Causing Cardiomyopathy Phenocopies and Synthetic Description of Involvements of Other Organs/Tissues
Disease
MIM #
Phenotype Inheritance Age of Onset
Disease
Gene Cardiac Phenotype
Extracardiac Markers/
Major Involvement
(Noncomprehensive) of
Other Organs
Speciﬁc
Treatment
Glycogen storage disease (GSD)
GSDII (Pompe disease, glycogen
storage disease II, acid
alpha-glucosidase/acid
maltase deﬁciency)
232300 AR Infant to young adult GAA HCM Skeletal muscle, liver ERT (gene
therapy;
substrate
reduction
therapy)
GSDIII (Forbes or Cori disease,
glycogen debranching enzyme)
232400 AR Childhood AGL HCM Liver, skeletal muscle,
hypoglycemia, growth
retardation
GSD IV (Anderson disease, glycogen
branching enzyme)
232500 AR Perinatal, congenital,
infant, childhood,
adult
GBE1 DCM Liver, skeletal muscle,
brain
GSD V (McArdle disease, glycogen
phosphorylase)
232600 AR Young adult PYGM DCM Skeletal muscle;
myoglobinuria
GSD 0 (muscle) (muscle glycogen
synthase
611556 AR Childhood GYS1 HCM Skeletal muscle
Other disorders of the glycogen metabolism
PRKAG2-related disease
Lethal congenital glycogen storage
disease of heart
261740 AD Young adult PRKAG2 HCM —
PRKAG2-related familial hypertrophic
cardiomyopathy
600858 AD Young adult PRKAG2 HCM —
Wolff-Parkinson-White syndrome 194200 AD Young adult PRKAG2 WPW with/without
HCM
—
Danon disease (lysosomal-associated
membrane protein 2)
300257 XL Childhood in males,
young adult in
females
LAMP2 HCM, HCM evolving
through dilation
and dysfunction,
LVNC
Skeletal muscle, cognitive
impairment in males,
pigmentary retinopathy
also in females
Lysosomal storage diseases: sphingolipidoses
Anderson-Fabry disease (alpha-
galactosidase deﬁciency)
301500 XL Childhood to adulthood GLA Symmetrical HCM Renal, ocular, nervous,
cutaneous,
gastrointestinal
systems
ERT
Anderson-Fabry disease—later onset,
cardiac variant
301500 XL Adult GLA HCM — ERT
GM1 gangliosidosis (beta-galactosidase
deﬁciency)
230500 AR Infancy (infantile form),
childhood (late-infantile/
juvenile form), adult
(chronic form)
GLB1 HCM, DCM Neurological and skeletal
systems,
hepatosplenomegaly
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MLD (Metachromatic leucodystrophy) 250100 AD Infancy (infantile form),
childhood (juvenile form),
adult (adult form)
ARSA RCM/DCM Skeletal muscle, nervous,
ocular systems
GM1 gangliosidosis with cardiac
involvement (beta-galactosidase
deﬁciency) [50e53]
230500 AR Infancy (infantile form),
childhood (juvenile form),
adult (adult form)
GLB1 HCM/DCM, mitral
valve thickening,
CAD
Skeletal muscle, nervous,
renal, ocular, and
cutaneous systems
GM2 gangliosidosis (Tay-Sachs disease) 272800 AR Infancy (infantile form),
childhood (juvenile
form), adult (adult
form)
HEXA Valve disease Nervous, ocular, auditory
GM2 gangliosidosis (Sandhoff-Jatzkewitz
disease) [54,55]
268800 AR Infancy (infantile form),
childhood (juvenile
form), adult (adult
form)
HEXB HCM, Mitral and aortic
valve disease
Nervous, skeletal muscle,
ocular systems
Gaucher disease (glucocerebrosidase
deﬁciency), types I, II and III,
perinatal lethal and type IIIC with
cardiovascular calciﬁcations (cardiac
variant)
230800 AR Childhood to young adult GBA (HK
gene)
Cardiovascular
calciﬁcations
Hemopoietic, nervous,
bone, cutaneous
systems,
hepatosplenomegaly
ERT
Niemann-Pick disease (types C1, D) [56] 257220 AR Infant, childhood, adult NPC1 Coronary artery and
valvular heart
disease
Nervous, bone, cutaneous
systems,
hepatosplenomegaly,
sea-blue histiocytes
Lysosomal storage diseases: mucopolysaccaridoses (degradation defects of glycosaminoglycans)
MPS I (Hurler and Scheie syndromes)
(iduronidase enzyme deﬁciency)
607014, 607016,
607015
AR Childhood to young adult DUA HCM Nervous, skeletal and joints,
ocular, cutaneous,
respiratory systems
ERT
MPS II (Hunter syndrome) 309900 XLR Late infancy to young adult IDS HCM Nervous, skeletal, ocular,
cutaneous, auditory
systems
ERT
MPS III A (Sanﬁlippo syndrome A) 252900 AR Infancy to young adult SGSH HCM, HF Nervous, skeletal, cutaneous
systems; abundant and
coarse, often blond hair
MPS III B (Sanﬁlippo syndrome B) 252920 AR NAGLU HCM, HF Nervous; skeletal, ocular,
auditory
MPS III C (Sanﬁlippo syndrome C) 252930 AR HGSNAT HCM, HF Nervous, skeletal, ocular,
hypertrichosis
MPS III D (Sanﬁlippo syndrome D) 252940 AR GNS HCM, HF Nervous, skeletal, ocular,
auditory, hypertrichosis
MPS IV A (Morquio syndrome A) 253000 AR Infancy to young adult GALNS Nervous, skeletal, ocular
MPS IV B (Morquio syndrome B) 253010 AR Infancy to young adult GLB1 HCM Nervous, skeletal, ocular
MPS VI (Maroteux-Lamy syndrome) 253200 AR Infancy to adult ARSB DCM Skeletal, integumental,
ocular, muscular,
hepatosplenomegaly
ERT
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TABLE 4. Continued
Disease
MIM #
Phenotype Inheritance Age of Onset
Disease
Gene Cardiac Phenotype
Extracardiac Markers/
Major Involvement
(Noncomprehensive) of
Other Organs
Speciﬁc
Treatment
MPS VII (Sly syndrome) 253220 AR Infancy to adult GUSB HCM Skeletal, nervous, possible
hepatomegaly and
mild ocular
MPS IX 601492 AR Infancy to young adult HYAL1 Heart involvement,
NOS
Skeletal, nervous, ocular
Lysosomal storage diseases: disorders of glycoprotein and glycosylation metabolism
Galactosialidosis or Goldberg syndrome
(cathepsin A defect)
256540 AR Infancy (early and late
infantile types),
childhood, adult
(juvenile/adult type)
CTSA HCM in late infantile
type, DCM
Nervous, skeletal, ocular,
cutaneous, auditory
systems; possible
hepatosplenomegaly
Mucolipidosis or sialidosis, type I and II 256550 AR Infancy to adult NEU1 DCM Nervous, skeletal, ocular,
cutaneous systems
Fucosidosis 230000 AR Infancy to adult FUCA1 DCM, HF Nervous, skeletal, ocular,
cutaneous (angiokeratoma)
systems
Alpha-mannosidosis 248500 AR Infancy to young adult MAN2B1 Possible heart
involvement, NOS
Nervous, skeletal, cutaneous,
auditory
Beta-mannosidosis 248510 AR Infancy to young adult MANBA Possible heart
involvement, NOS
Nervous, skeletal, auditory,
cutaneous
Aspartylglucosaminuria 208400 AR Infancy to young adult AGA HCM Nervous, skeletal, cutaneous
Schindler disease juvenile (Kanzaki
disease, adult form)
609241, 609241 AR Childhood, adult NAGA HCM Nervous, skeletal, muscle,
cutaneous
Disorders of amino acid and organic
acid metabolism
Methylmalonic aciduria 251000 AR Infancy to young adult MUT DCM Systemic
Beta-ketothiolase deﬁciency 203750 AR Infancy ACAT1 DCM Liver, kidney, ketoacidotic
attacks, lethargy
Tyrosinemia I 276700 AR Infancy to young adult/adult FAH HCM Liver, kidney, mental
retardation
Hyperoxaluria I (oxalosis I) 259900 AR Infancy to childhood/adult AGXT HCM Kidney
Hyperoxaluria II (oxalosis II) 260000 AR Infancy to childhood/adult GRHPR HCM Kidney
Alkaptonuria (homogentisate
1,2-dehydrogenase deﬁciency)
203500 AR Infancy to old age HGD Aortic valve disease Kidney
Niemann-Pick ERT ¼ enzyme replacement therapy; HF ¼ heart failure; NOS ¼ not otherwise speciﬁed; XLR ¼ X-linked recessive; other abbreviations as in Table 1.
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suspecting a mitochondrial disease in patients with car-
diomyopathy at onset or as ﬁrst clinical manifestation.
Mitochondrial HCM initially shows symmetrical LV hy-
pertrophy, and subsequently evolves through LV
dysfunction and dilation. A number of cardiac (short PR
interval, pre-excitation syndrome, AVB) or noncardiac
(hearing loss, myopathy, palpebral ptosis, nonvascular
neurological involvement, mental retardation) markers, or
biochemical (elevated serum creatine phosphokinase
[[sCPK], lactacidemia) indicators in probands and rela-
tives provide diagnostic clues [35].
The MOGE(S) system allows a comprehensive sum-
mary of the clinical and genetic status of the family once
the diagnosis has been made and family screening
completed. The availability of the functional status (S)
becomes especially important in asymptomatic relatives
with manifest causative gene defect. Both cardiac and
extracardiac traits contribute to clinical recognition of
phenocopies (Table 4) [35,50-56]. A systematic approach
leads to better characterization of cardiomyopathic disor-
der and could identify the need for pathological conﬁr-
mation of the etiological basis of the disease, such as in
AFD (Fig. 6) and in Danon Disease (Fig. 7). An accurate
diagnosis is mandatory for genetic counseling and disease
management; for example, the availability of enzyme
replacement therapy in AFD may change the natural his-
tory of the disease and prevent (or delay) the end-stage
disease.TA
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.MOGE(S) NOMENCLATURE FOR RCM
RCM is clinically characterized by altered relaxation and
abnormal LV ﬁlling, biatrial dilation, in the absence of sig-
niﬁcant LV hypertrophy (Table 2). The lack of hypertrophy
distinguishes RCM from HCM with restrictive pattern.
Troponinopathies and desminopathies are typical examples
of pure RCM; the former is not associated with conduction
disease, whereas the latter is associated with AVB. Tropo-
ninopathies are encountered as de novo or inherited as an
AD disease, whereas the desminopathies are inherited as AD
(50%), AR (25%), or de novo (25%) [57,58]. The differential
diagnosis of desminopathy is based on the presence of AVB
and its association with myopathy; a ﬁne-needle biopsy of
the skeletal muscle immunostained with anti-desmin anti-
bodies may provide the ﬁnal diagnosis. Alternatively,
endomyocardial biopsy may demonstrate intracellular
osmiophilic granuloﬁlamentous inclusions that immunor-
eact with anti-desmin antibodies (Fig. 8). Pure RCM due
to defects of troponin genes, TNNI3 in particular, may
show absence of myocyte hypertrophy on histology but the
presence of myocyte disarray otherwise characteristic of
sarcomeropathy [59]. The clinical distinction of the tropo-
ninopathy [60,61] and desminopathy is important because
of the high arrhythmogenic risk in troponinopathy and the
negligible risk in desminopathy. In a recent meta-analysis
including desmin-related diseases, both myopathies and
cardiomyopathies, sudden death was reported in 2 of 195GLOBAL HEART, VOL. 8, NO. 4, 2013 377
December 2013: 355-382
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378DES mutation carriers [62]. On the other hand, desminop-
athy shows high risk of AVB. Both entities share a very high
penetrance, and almost all mutated individuals demonstrate
manifest disease by the age of 40 years [63]. MOGE(S) ap-
plies to RCM as follows.
MR[AVB] OHDM GAD EG-Des[p.Gly84Ser] SC-III represents
morphofunctional phenotype (M): restrictive cardiomy-
opathy (R) with AVB; organ (O) involvement: heart (H)
and skeletal muscle (M); genetic/familial (G) with auto-
somal dominant (AD) transmission; etiology (E): genetic
(G) caused by the p.Gly84Ser mutation in the Desmin
gene; ACC/AHA stage (S) C, NYHA III.
ME(R) [AVB] OHDM GAD EG-Des[p.Gly84Ser] SA-I repre-
sents morphofunctional phenotype (M): “early” (E)
restrictive cardiomyopathy with AVB; organ (O) involve-
ment: heart (H) and skeletal muscle (M); genetic/familial
(G) with autosomal dominant (AD) transmission; etiology
(E): genetic (G) caused by the p.Gly84Ser in the Desmin
gene; ACC/AHA stage (S) A, NYHA I.
M0 O0 GAD EG-Des[p.Gly84Ser] SA-I represents morpho-
functional phenotype (M): “unaffected” (0) by cardiomy-
opathy; organ (O) involvement: none (¼absence of any
cardiac phenotype); genetic/familial (G) with autosomal
dominant (AD) transmission; etiology (E): genetic and
caused by the p.Gly84Ser mutation in the Desmin gene;
ACC/AHA stage (S) A, NYHA I.MOGE(S) CLASSIFICATION FOR AMYLOID HEART
DISEASE
Amyloidosis represents a distinct and unique condition of
extracellular inﬁltrative disease. Most cardioamyloidoses
are in the context of systemic diseases (genetic or nonge-
netic). Its inclusion in MOGE(S) is supported by the car-
diac phenotype and clinical presentation as HCM or RCM
that must be distinguished from other HCM and RCM.
Amyloid shows distinct staining properties (pink-violet
color with hematoxylin and eosin, apple-green birefrin-
gence with Congo Red under polarized light, and magenta
color with crystal violet) and ultrastructural characteristics
(ﬁbrils of 7.5- to 10-nm diameter), regardless of the amy-
loidogenic protein [64,65]. Amyloidosis may be systemic
or localized, the former including primary (AL), secondary
(AA), and genetic (multiple and different genes) forms. The
heart shows inﬁltration in the interstitial spaces, vessel
walls of epicardial coronary arteries and intramural small
vessels, cardiac valves, and epicardial fat [66]. The heart is
usually hypertrophied, with thickened cardiac valves, and
shows a restrictive functional pattern. The typical patient is
an adult or an old individual of either sex with a long-
standing history of nonspeciﬁc symptoms; family history
is positive for heart failure, renal or multiorgan failure in
heritable forms. The children with familial Mediterranean
fever caused by mutations of the gene Marenostrin (MEFV)
may show amyloidosis of kidney, skin, thyroid; the heart is
less likely to be involved [67].In most cases of cardiac amyloidosis, there is an echo-
ECG mismatch with increased LV wall thickness and
decreased ECG voltages. The amyloidogenic protein can
be identiﬁed by immunoelectron microscopy study of the
endomyocardial biopsy (or the peri-umbilical fat in sys-
temic forms). The genetic testing is mandatory in familial
amyloidosis [68,69]; the investigation of the family mem-
bers not only may provide early or pre-clinical diagnosis,
but also contributes to understanding the natural history of
the disease. The MOGE(S) system facilitates the description
of the amyloid cardiomyopathy. MOGE(S) applies to car-
diac amyloidosis as follows.
MHDR(ECG voltages) OHDK GN EA-L SB-II represents
morphofunctional phenotype (M): hypertrophic cardio-
myopathy with restrictive pattern (HDR), low ECG
voltages; organ (O) involvement: heart (H) and kidney
(K); genetic/familial (G): negative family history (N) (and/
or screening); etiology (E): amyloidosis (A), amyloido-
genic light chain lambda (L); ACC/AHA stage (S) B,
NYHA II.
MOGE(S) NOMENCLATURE FOR DCM
DCM is characterized by the presence of LV dilation and LV
systolic dysfunction in the absence of other disorders sufﬁ-
cient to cause global systolic impairment (Table 2). Right
ventricular dilation and dysfunction can be present, but not
necessary, for the diagnosis [8]. More than 50% of the DCM
cases are familial [10]. Although all DCM phenotypically
look alike, most of them are distinct genetic diseases. Mu-
tations inmore than 40 genes have been described (Table 1),
leading to extreme genetic heterogeneity [70]. Most familial
DCMs are AD, and a minority is X-linked recessive, auto-
somal recessive, or matrilineal [10]. The most common
disease gene is Lamin A/C, and the laminopathy constitutes
8% of all DCMs. Dystrophin gene defects account for up to
7% of male patients with DCM; most of these patients show
an increase in sCPK without apparent myopathy [16,71,72]
(Fig. 9). About one-fourth of the DCM cases have been
recently attributed to the mutations in the giant Titin (TTN)
gene [73]. The elastic protein titin is expressed in car-
diomyocytes in 2 main isoforms, N2B (stiffer spring) and
N2BA (more compliant spring). Titin-isoform switching is
considered a mechanism for increased myocardial passive
stiffness found in patients with heart failure with preserved
LVEF [74]. While waiting for conﬁrmatory studies, Titin
remains an important disease gene. DCM patients with TTN
mutations do not show disease-speciﬁc clinical markers
[73]. The laminopathies are clinically characterized by
conduction tissue disease in up to 80% of patients; the
remaining patients demonstrate atrial ﬁbrillation or an
ARVC-like phenotype [75]. Dystrophinopathy is associated
with severely enlarged and dysfunctional ventricles, and
increased sCPK [16,72]. Zaspopathies [76] and tafazzino-
pathies show either LVNC or increased trabeculations in the
setting of DCM [77]; the tafazzinopathies typically occur in
infancy and characteristically show cyclic neutropenia, oralGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382
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aphthous ulcers, and hypocholesterolemia [77]. A small
number of DCM patients are characterized by autosomal
recessive inheritance and are usually brought to the attention
of cardiologists when being evaluated for lipid storage dis-
ease in a multidisciplinary context. Table 5 summarizes the
known disease genes as well as the cardiac phenotypes
typically expressed in these disorders [78e83]. Cardiomy-
opathy, mostly DCM, is one of the common traits recurring
in these syndromes, and in some of them it may be the sole
manifestation of the disease [79,84,85].
All aforesaid information, including the common car-
diac phenotype, the clinical markers, or red ﬂags that may
occur in patients/carriers of mutations of the same gene, are
systematically organized in the MOGE(S) system, thus
generating a common pheno-molecular language that can
be easily adopted by clinicians in their daily practice,
without the risk of missing out on any necessary infor-
mation. MOGE(S) applies to DCM as follows.
MD[AVB] OH GAD EG-LMNA[p.Leu197ProfsX2] SC-II repre-
sents morphofunctional phenotype (M): dilated cardio-
myopathy with atrioventricular block; organ (O)
involvement: heart (H); genetic/familial (G) with auto-
somal dominant (AD) transmission; etiology (E): genetic
and caused by the p.Leu197Pro fs X2 mutation in the
LMNA gene; ACC/AHA stage (S) C, NYHA II.
ME(D) OH GAD EG-LMNA[p. Leu197ProfsX2] SA-I represents
morphofunctional phenotype (M): “early” (E) dilated
cardiomyopathy (for example, increased LV end-diastolic
dimension with normal LV function, or borderline LV
function); organ (O) involvement: heart (H); genetic/fa-
milial (G) with autosomal dominant (AD) transmission;
etiology (E) is genetic and caused by the p.Leu197Pro fs
X2 mutation in the LMNA gene; ACC/AHA stage (S) A,
NYHA I.
ME(D) OH GAD EG-NA SA-I represents morphofunc-
tional phenotype (M): “early” (E) dilated cardiomyopathy
(see example in the preceding text); organ (O) involve-
ment: heart (H); genetic/familial (G) with autosomal
dominant (AD) transmission; etiology (E): genetic but the
mutations is not yet available (NA) (genetic test either
ongoing or to be done, but feasible); ACC/AHA stage (S) A,
NYHA I.
M0 O0 GAD EG-LMNA[p. Leu197ProfsX2] SA-I represents
morphofunctional phenotype (M): “unaffected” (0) by
cardiomyopathy; organ (O) involvement: none (0) (¼
absence of any cardiac phenotype); genetic/familial (G)
with autosomal dominant (AD) transmission; etiology (E):
genetic (G), healthy carrier of the p.Leu197Pro fs X2
mutation in the LMNA gene that causes the disease in the
family; ACC/AHA stage (S) A, NYHA I.
The genetic testing in future is expected to inﬂuence
clinical decision making for primary prevention of sudden
death and ICD implantation. In the current guidelines the
severely depressed LVEF constitutes the major indication
for ICD implantation in patients with DCM [11e13]. It is
now becoming increasingly evident that laminopathies
carry high arrhythmogenic risk [15,20] even when theyGLOBAL HEART, VOL. 8, NO. 4, 2013
December 2013: 355-382may not meet guideline recommendations for ICD im-
plantation. On the other hand, some genes and genetic
variants may not be at high risk even though they may
result in low LVEF [16]. A group of DCM caused by
mutations in genes typically related to ARVC have a high
risk of life-threatening arrhythmias and may deserve ICD
implantation even if they fall short of guideline-based
recommendations [11e13]. As we accumulate more
knowledge and experience, the indications for ICD im-
plantation will be modiﬁed, made more speciﬁc, and
personalized.
MOGE(S) NOMENCLATURE FOR ARVC
Although predominantly affecting the RV, the spectrum of
ARVC now includes possible biventricular involvement as
well as the left dominant arrhythmogenic cardiomyopathy
[86], referred to as arrhythmogenic cardiomyopathy
(ACM)/ARVC in the recent HRS/EHRA Expert Consensus
Statement on the State of Genetic Testing for the Chan-
nelopathies and Cardiomyopathies [87]. Although all
ACM/ARVC phenotypes are associated with mutations in
desmosome genes [88,89], mutations in typically DCM-
related genes have also been observed in ARVC-like
phenotypes [75]. The practical implication of such
genotype-phenotype correlative studies would be to
determine whether the arrhythmogenic risk is better
associated with the disease gene or the clinical phenotype.
MOGE(S) applies to ARVC/ACM as follows.
MA[ε] OH GAD EG-DSG2[p.Glu1020AlafsX18] SA-I repre-
sents morphofunctional phenotype (M): ARVC with
ε wave; organ (O) involvement: heart (H); genetic/familial
(G) with autosomal dominant (AD) transmission; etiology
(E): genetic (G) and caused by the p.Glu1020Ala fs X 18
mutation in the DSG2 gene; ACC/AHA stage (S) A,
NYHA I.
ME(A) OH GAD EG-DSG2[p.Glu1020AlafsX18] SA-I repre-
sents morphofunctional phenotype (M): “early” (E)
arrhythmogenic cardiomyopathy (for example, with mi-
nor ECG and/or echocardiographic criteria); organ (O)
involvement: heart (H); genetic/familial (G) with auto-
somal dominant (AD) transmission; etiology (E): genetic
(G) and caused by the p.Glu1020Ala fs X 18 mutation in
the DSG2 gene that causes the disease in the family; ACC/
AHA stage (S) A, NYHA I.
M0 O0 GAD EG-DSG2[p.Glu1020AlafsX18] SA-I represents
morphofunctional phenotype (M): “unaffected” (0) by
cardiomyopathy; organ (O) involvement: none (0)
(¼absence of any cardiac phenotype); genetic/familial (G)
with autosomal dominant (AD) transmission; etiology (E):
genetic (G), healthy carrier of the p.Glu1020Ala fs X 18
mutation in the DSG2 gene that causes the disease in the
family; ACC/AHA stage (S) A, NYHA I.
MOGE(S) NOMENCLATURE FOR LVNC
Left ventricular noncompaction (LVNC) is a morphological
entity characterized by an excessive trabeculation of the LV379
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380[90,91] (Table 2). Diagnostic criteria are based on echo and
cardiac magnetic resonance imaging wherein the non-
compacted ventricular muscle layer is substantially thicker
than the compact layer [91]. Most LVNC patients are
asymptomatic, and the diagnosis is often incidental. The
LVNC can occur as isolated morphological phenotype [92]
in association with LV systolic dysfunction or with LV
hypertrophy. LVNC has been associated with both DCM
and HCM, and with mutations in genes typically causing
DCM and HCM [93]. LVNC is a typical trait in Barth
syndrome [94] (Fig. 10), and it has been reported to occur
more frequently in carriers of LDB3 gene mutations.
Although true LVNC is rare, hypertrabeculation of the LV
is common and may be associated with increased throm-
boembolic risk. The MOGE(S) system distinguishes LVNC
with LV dilation and dysfunction (MLVNCþD) or with LV
hypertrophy (MLVNCþH) from pure LVNC (MLVNC).THE MOGE(S) CLASSIFICATION IN CLINICAL
PRACTICE
The MOGE(S) system proposes a nosology that addresses
5 simple attributes of cardiomyopathies, including mor-
phofunctional characteristic (M), organ involvement (O),
genetic or familial inheritance pattern (G), and an explicit
etiological annotation (E) with details of genetic defect or
underlying disease/cause, followed by optional information
about the functional status (S) using the ACC/AHA stage
and NYHA functional class. Although the application of
this nosology allows complete description of the diseases,
the full notation may appear complex. It is expected that
routine nomenclature will continue to be described by
the standard, currently practiced morphology, and the
proposed nosology is not meant to replace the morpho-
logical description. A dilated cardiomyopathy will be called
dilated cardiomyopathy, but the complete description of
the disease process would be best served by the descriptive
terminology such as MOGE(S). In fact, AHA suggests
genotyping to supersede the phenotypic description, which
is opposed by the ESC; the proposed MOGE(S) system is a
compromise. It is prudent to consider an example from the
ﬁeld of oncology. Pathological staging in a patient with
lung cancer who has been treated with neoadjuvant ther-
apy and still has multiple residual nodules in the ipsilateral
lung and different lobes, has distant metastases, and lymph
nodes show isolated tumor cells only, is described using
TNM staging as follows: ypT4(m) N0 (iþ) M1b G3 LVI þ
R2. y denotes that the patient has received neoadjuvant
therapy prior to resection, p presents pathological stage
after resection, T4 offers the extent of tumor which in this
case has multiple residual tumor nodules (m) in different
lobes of ipsilateral lung, N denotes the nodal status
[N0(iþ)] isolated tumor cells only in a lymph node that are
considered node negative or N0, and M represents me-
tastases where M1b means distant metastases (in contrast
to M1a, which is thoracic metastases such as contralateral
lung, pleural nodules or malignant pleural, or pericardialeffusion). G in this staging is histological grade (1 ¼ well
differentiated; 2 ¼ moderate; 3 ¼ poorly differentiated),
LVI þ represents lymphovascular invasion (LVI, absent),
and R is residual disease after treatment (R0 ¼ no residual
disease; R1 ¼ microscopic residual disease; R2 ¼ grossly
identiﬁed residual disease). Howsoever complex it may
sound, oncologists are expected to use standard TNMstaging.
TNM nosology is constantly expanding, is very ﬂexible, but
ensures completeness. Simply looking at [ypT4(m) N0(iþ)
M1b G3 LVIþ R2] gives physicians all the information about
the patient in question. However, in the common practice,
this patient is considered to have lung cancer. Therefore, the
MOGE(S) example MD[AVB] OH GAD EG-LMNA[p. Arg190Trp] is
complete notation for a patient presenting with a speciﬁc
DCM. The authors of the MOGE(S) nomenclature have
developed an easy web-assisted application that can be
conveniently used in daily clinical practice for complete and
descriptive classiﬁcation of cardiomyopaythy (http://moges.
biomeris.com).CONCLUSIONS
We propose a descriptive nosology that combines mor-
phofunctional trait and organ/system involvement with fa-
milial inheritance pattern, identiﬁed genetic defect, or other
etiologies. Aswith the universal TNM staging for tumors, it is
expected that this description will be improved, revised,
modiﬁed, and made more comprehensive and user friendly.
It will allow better understanding of the disease, allow easier
communication among physicians, and help develop
multicenter/multinational registries to promote research in
diagnosis and management of cardiomyopathies.REFERENCES
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